First of a kind AI system: LLM classifiers trained via reinforcement learning to uncover outcome-based patterns in drug discovery research papers beyond human comprehension.

First of a kind AI system: LLMs trained as classifiers to uncover outcome-based patterns in drug discovery research papers beyond human comprehension.

How it works

Runtime 1:40

In this video

Follow the story behind Explority in motion – showing how our AI is trained to outperform the pharmaceutical industry’s low early-stage success rates.

50.7%

of approved orphan therapies came from the top 8% of highest-scored research

5-year

earlier predictions to shorten research-to-approval time

31%

higher success rate in therapies selected by Explority AI

50.7%

of approved orphan therapies came from the top 8% of highest-scored research

5-year

earlier predictions to shorten research-to-approval time

31%

higher success rate in therapies selected by Explority AI

Female scientist in gloves using a microscope beside test tubes, with overlay text about merging biotech, AI, and human-centric research.

De-risking discovery

The first AI system capable of forecasting the likelihood of approval for early-stage therapies, sourcing orphan therapies, that will outperform the industry’s average preclinical success rate.

De-risking discovery

The first AI system capable of forecasting the likelihood of approval for early-stage therapies, sourcing orphan therapies, that will outperform the industry’s average preclinical success rate.

1M+ drug discovery papers across 5,846 rare diseases linked to clinical outcomes in training

31% higher success rates over average assets

Validated on 83,501 novel drug candidates reported in the literature in a quasi-prospective test — Explority AI sources 50.7% of approved orphan therapies at the stage of published research while outperforming the average preclinical success rate.

5-year competitive edge in portfolio

By continuously analyzing 100,000+ of drug discovery papers across 5,846 rare diseases annually, Explority AI identifies the next successful first- and best-in-class therapies up to five years before they receive orphan designation, across small molecules, antibodies, therapeutic proteins, RNAs, gene and cell therapies.

How Explority AI is trained

Man in a white shirt focused on a desktop computer displaying charts and data in a softly lit workspace.

De-Risking Decisions

De-risking early-stage decisions

Big Pharma

Who to partner with?

Big Pharma

Who to partner with?

Biotech companies

Which drugs to develop?

Biotech companies

Which drugs to develop?

Bio VCs

In what ideas to invest?

Bio VCs

In what ideas to invest?

Validation

Assessing
Explority AI
precision

Quasi-prospective setup

Trained on literature published up to 2019, we validated our LLMs on all 83,501 new drug candidates mentioned in these texts and used new orphan drug designations from 2019 to 2025 as positive outcomes.

Results across 5,846 rare diseases

Explority AI system identified 50.7% of orphan therapies that would reach approval – on average 2.5 years earlier and with greater precision than the industry’s average success rate.

Our solutions

How we help accelerate research and decision-making.

Solutions for all early-stage rare disease decisions with data-driven preclinical probability of success forecasts.

Glowing red biological cells seen under a microscope, suggesting cellular or molecular research imagery.

Automated deal soursing

Big Pharma & VC

Automated deal soursing

Big Pharma & VC

De-risked pipeline

Biotech & Big pharma

De-risked pipeline

Biotech & Big pharma

Drug repurposing

Biotech & Big pharma

Drug repurposing

Biotech & Big pharma

Welcome to Explority

Tomorrow’s challenges demand today’s boldest ideas. Our mission is to redefine what’s possible—where pharma meets AI.

Book a demo

First of a kind AI system: LLM classifiers trained via reinforcement learning to uncover outcome-based patterns in drug discovery research papers beyond human comprehension.

First of a kind AI system: LLMs trained as classifiers to uncover outcome-based patterns in drug discovery research papers beyond human comprehension.

How it works

50.7%

5-year

31%

50.7%

5-year

31%

1M+ drug discovery papers across 5,846 rare diseases linked to clinical outcomes in training

De-Risking Decisions

De-risking early-stage decisions

Assessing Explority AI precision

How we help accelerate research and decision-making.

Solutions for all early-stage rare disease decisions with data-driven preclinical probability of success forecasts.

Automated deal soursing

Automated deal soursing

De-risked pipeline

De-risked pipeline

Drug repurposing

Drug repurposing

Tomorrow’s challenges demand today’s boldest ideas. Our mission is to redefine what’s possible—where pharma meets AI.

Tomorrow’s challenges demand today’s boldest ideas. Our mission is to redefine what’s possible—where pharma meets AI.

Assessing
Explority AI
precision